Trevi Therapeutics

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell TRVI and other ETFs, options, and stocks.

About TRVI

Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of Haduvio to treat serious neurologically mediated conditions. It includes treatment of chronic pruritus associated with prurigo nodularis and chronic cough in patients with idiopathic pulmonary fibrosis, and levodopa-induced dyskinesia in patients with Parkinson’s disease.

CEO

Jennifer L. Good

CEOJennifer L. Good

Employees

Employees26

Headquarters

New Haven, Connecticut

HeadquartersNew Haven, Connecticut

Founded

2011

Founded2011

Employees

Employees26

TRVI Key Statistics

Market cap

1.14B

Market cap1.14B

Price-Earnings ratio

-23.75

Price-Earnings ratio-23.75

Dividend yield

—

Dividend yield—

Average volume

1.69M

Average volume1.69M

High today

$10.03

High today$10.03

Low today

$9.37

Low today$9.37

Open price

$9.67

Open price$9.67

Volume

443.14K

Volume443.14K

52 Week high

$10.16

52 Week high$10.16

52 Week low

$2.36

52 Week low$2.36

TRVI News

TipRanks 3d

Trevi Therapeutics Completes Key Phase 1 Drug Interaction Study

Trevi Therapeutics ((TRVI)) announced an update on their ongoing clinical study. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off!...

Simply Wall St 5d

Does Trevi Therapeutics’ Scientific Recognition Hint at Broader Momentum in Chronic Cough Innovation?

Trevi Therapeutics announced that two abstracts highlighting key data from clinical trials of its investigational therapy, oral nalbuphine ER for chronic cough,...

Analyst ratings

100%

of 12 ratings

Buy

100%

Hold

Sell

People also own

Based on the portfolios of people who own TRVI. This list is generated using Robinhood data, and it’s not a recommendation.